H. Iqbal, M. Ishfaq, and A. Wahab, Therapeutic modalities to combat leishmaniasis, a review, Asian Pacific J Trop Dis, vol.6, pp.1-5, 2016.

I. Kevric, M. A. Cappel, and J. H. Keeling, New world and old world leishmania infections: a practical review, Dermatol Clin, vol.33, pp.579-593, 2015.

J. Alvar, . Id, and C. Bern, Leishmaniasis worldwide and global estimates of its incidence, PLoS One, vol.7, p.35671, 2012.

S. Sundar and J. Chakravarty, An update on pharmacotherapy for leishmaniasis, Expert Opin Pharmacother, vol.16, pp.1-16, 2014.

E. C. Torres-santos, D. L. Moreira, and M. Kaplan, Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis, Antimicrob Agents Chemother, vol.43, pp.1234-1241, 1999.

P. Boeck, C. A. Bandeira-falcão, and P. C. Leal, Synthesis of chalcone analogues with increased antileishmanial activity, Bioorganic Med Chem, vol.14, pp.1538-1545, 2006.

M. Chen, S. B. Christensen, and T. G. Theander, Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani, Antimicrob Agents Chemother, vol.38, pp.1339-1344, 1994.

L. Zhai, M. Chen, and J. Blom, The antileishmanial activity of novel oxygenated chalcones and their mechanism of action, J Antimicrob Chemother, vol.43, pp.793-803, 1999.

C. B. Mattos, D. F. Argenta, and G. Melchiades, Nanoemulsions containing a synthetic chalcone as an alternative for treating cutaneous leshmaniasis: optimization using a full factorial design, Int J Nanomedicine, vol.10, pp.5529-5542, 2015.

. Dndi and . Infoleish, Boletim informativo da redeLEISH, 2016.

M. P. Oliveira-neto, A. Schubach, and M. Mattos, Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil -an area of Leishmania (V.) braziliensis transmission, Int J Dermatol, vol.36, pp.463-468, 1997.

I. Esfandiarpour, S. Farajzadeh, and Z. Rahnama, Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis, Int J Dermatol, vol.51, pp.1221-1225, 2012.

B. Salah, A. , B. Messaoud, N. Guedri, and E. , Topical paromomycin with or without gentamicin for cutaneous leishmaniasis, N Engl J Med, vol.368, pp.524-532, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-00793585

T. Garnier and S. L. Croft, Topical treatment for cutaneous leishmaniasis, Curr Opin Investig Drugs, vol.3, pp.538-544, 2002.

K. Bocxlaer, V. Van-yardley, and S. Murdan, Drug permeation and barrier damage in Leishmania-infected mouse skin, J Antimicrob Chemother, vol.71, pp.1578-1585, 2016.

T. A. Ahmed, H. M. Ibrahim, and A. M. Samy, Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability, AAPS PharmSciTech, vol.15, pp.772-780, 2014.

R. Nicolete, D. F. Santos, . Dos, and L. H. Faccioli, The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response, Int Immunopharmacol, vol.11, pp.1557-1563, 2011.

Y. Wang, W. Qu, and S. H. Choi, FDA's regulatory science program for generic PLA/PLGA -based drug products, Am Pharm Rev, vol.19, pp.5-9, 2016.

A. J. Sousa-batista, W. Pacienza-lima, and N. Arruda-costa, Depot subcutaneous injection with chalcone CH8-loaded poly(lactic-co-glycolic acid) microspheres as a single-dose treatment of cutaneous leishmaniasis, Antimicrob Agents Chemother, vol.62, pp.1822-1839, 2018.

B. Rossi-bergmann, E. C. Torres-santos, and R. A. Yunes, S ?ntese e uso de chalconas para tratamento de doenc¸as parasit arias [Synthesis and use of chalcones for the treatment of parasitic diseases, 2004.

, Hansen solubility parameters: a user's handbook, 2007.

D. W. Van-krevelen, Properties of polymers: their correlation with chemical structure: their numerical estimation and prediction from additive group contributions, 2009.

N. Schafroth, C. Arpagaus, and U. Y. Jadhav, Nano and microparticle engineering of water insoluble drugs using a novel spray-drying process, Colloids Surfaces B Biointerfaces, vol.90, pp.8-15, 2012.

J. O'brien, W. I. Orton, and T. , Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity, Eur J Biochem, vol.267, pp.5421-5426, 2000.

D. S. Bredt and S. H. Snyder, Nitric oxide: a physiologic messenger molecule, Annu Rev Biochem, vol.63, pp.175-195, 1994.

Z. Lavra and D. Pereira-de-santana, Solubility and dissolution performances of spray-dried solid dispersion of Efavirenz in Soluplus, Drug Dev Ind Pharm, vol.9045, pp.1-13, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01619242

C. G. Madsen, A. Skov, and L. Jørgensen, Effect of mixed solvents on polymer conformation -correlation between the hildebrand/hansen solubility parameters and the intrinsic viscosity of polymer solutions, Annu Trans Nord Rheol Soc, vol.21, pp.347-352, 2013.

S. Schenderlein and M. L?-uck, Partial solubility parameters of poly(D,L-lactide-co-glycolide), Int J Pharm, vol.286, pp.19-26, 2004.

D. J. Greenhalgh, A. C. Williams, and P. Timmins, Solubility parameters as predictors of miscibility in solid dispersions, J Pharm Sci, vol.88, pp.1182-1190, 1999.

J. A. Baird and L. S. Taylor, Evaluation of amorphous solid dispersion properties using thermal analysis techniques, Adv Drug Deliv Rev, vol.64, pp.396-421, 2012.

P. J. Marsac, S. L. Shamblin, and L. S. Taylor, Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility, Pharm Res, vol.23, pp.2417-2426, 2006.

H. Folttmann and A. Quadir, Polyvinylpyrrolidone (PVP) -one of the most widely used excipients in pharmaceuticals: an Overview, Drug Deliv Technol, vol.8, pp.22-27, 2008.

J. Champion, A. Walker, and S. Mitragotri, Role of particle size in phagocytosis of polymeric microspheres, Pharm Res, vol.25, pp.1815-1821, 2008.

M. Gaumet, A. Vargas, and R. Gurny, Nanoparticles for drug delivery: the need for precision in reporting particle size parameters, Eur J Pharm Biopharm, vol.69, pp.1-9, 2008.

J. Siepmann, R. A. Siegel, and M. J. Rathbone, Fundamentals and applications of controlled release drug delivery, 2012.

A. Paudel, D. Raijada, and J. Rantanen, Raman spectroscopy in pharmaceutical product design, Adv Drug Deliv Rev, vol.89, pp.3-20, 2015.

F. Wan and M. Yang, Design of PLGA-based depot delivery systems for biopharmaceuticals prepared by spray drying, Int J Pharm, vol.498, pp.82-95, 2015.

. Diefenbach-a, H. Schindler, and N. Donhauser, Type 1 interferon (IFNalpha/beta) and type 2 nitric oxide synthase regulate the innate immune response to a protozoan parasite, Immunity, vol.8, pp.77-87, 1998.

H. W. Murray and C. F. Nathan, Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani, J Exp Med, vol.189, pp.741-746, 1999.

M. Qadoumi, I. Becker, and N. Donhauser, Expression of inducible nitric oxide synthase in skin lesions of patients with American cutaneous leishmaniasis, Infect Immun, vol.70, pp.4638-4642, 2002.

P. M. Sivakumar, P. K. Prabhakar, and M. Doble, Synthesis, antioxidant evaluation, and quantitative structure-activity relationship studies of chalcones, Med Chem Res, vol.20, pp.482-492, 2011.

F. Herencia, . Ferr, . Ml, and A. Ubeda, Novel anti-inflammatory chalcone derivatives inhibit the induction of nitric oxide synthase and cyclooxygenase-2 in mouse peritoneal macrophages, FEBS Lett, vol.453, pp.129-134, 1999.

J. Rojas, J. N. Dom-inguez, and J. E. Charris, Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase, Eur J Med Chem, vol.37, pp.699-705, 2002.